百特醫療 (BAX) 2017 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this call is being recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.

    各位女士、各位先生,早安,歡迎參加百特國際(Baxter International)2017 年第三季財報電話會議。(接線員指示)提醒各位,本通話由百特錄音並受著作權保護。未經百特許可,不得錄音或轉播。如有任何異議,請立即中斷連線。

  • I would now like to turn the call over to Ms. Clare Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.

    現在我想把電話交給百特國際投資人關係副總裁 Clare Trachtman 女士。Trachtman 女士,請開始。

  • Clare Trachtman - VP of IR

    Clare Trachtman - VP of IR

  • Thanks, Candace. Good morning, and welcome to our Third Quarter 2017 Earnings Conference Call. Joining me today are Joe Almeida, Baxter's Chairman and Chief Executive Officer; and Jay Saccaro, Baxter's Chief Financial Officer.

    謝謝你,Candace。各位早安,歡迎參加我們 2017 年第三季財報電話會議。今天與我一同出席的有百特董事長兼執行長 Joe Almeida,以及百特財務長 Jay Saccaro。

  • On the call this morning, we will be discussing Baxter's third quarter 2017 financial results along with our updated outlook for 2017. As a reminder, we have posted a supplemental presentation to complement this morning's discussion. This presentation, along with related non-GAAP reconciliations, could be accessed on Baxter's external website in the Investors section under Events & Presentations.

    今天上午的電話會議中,我們將討論百特 2017 年第三季財務結果,以及我們對 2017 年的最新展望。提醒各位,我們已發布一份補充簡報,以配合今天上午的討論。該簡報以及相關的非 GAAP 調節表,可於百特對外網站的「投資人」專區中「活動與簡報(Events & Presentations)」項下取得。

  • With that, let me start our prepared remarks by reminding everyone that this presentation, including comments regarding our financial outlook, new product development, business development and regulatory matters, contain forward-looking statements that involve risks and uncertainties. And of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more details concerning factors that could cause actual results to differ materially.

    接下來,在開始我們的預先準備發言之前,先提醒各位:本簡報(包含關於我們財務展望、新產品開發、業務開發與法規事項的評論)包含前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。關於可能導致實際結果與預期有重大差異的因素,請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得更多資訊。

  • In addition, on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of the non-GAAP financial measures being discussed today to the comparable GAAP financial measures is included in our earnings release issued this morning and available on our website.

    此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續性業務表現。今日討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已納入我們今早發布的財報新聞稿,並可於我們網站取得。

  • Now I'd like to turn the call over to Joe. Joe?

    現在我想把電話交給 Joe。Joe?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Thank you, Clare, and good morning, and thanks for joining us today. I'll get started with an overview of our third quarter results, then I'll share some key highlights for the quarter that reflect Baxter's accelerating momentum around innovation and drive towards sustainable top-quartile performance. I'll also briefly address our response to the natural disasters that have recently devastated parts of the Americas and Caribbean and the related projected impact on our operations in the fourth quarter. Finally, I will pass it over to Jay, who'll walk through our third quarter results and financial outlook in more detail. We'll close with Q&A.

    謝謝你,Clare,各位早安,也感謝各位今天加入我們。我將先概述第三季業績,接著分享本季幾項重點,反映百特在創新方面加速推進的動能,以及朝向可持續的同業頂尖(top-quartile)表現所做的努力。我也會簡要說明我們對近期重創美洲與加勒比海部分地區的天然災害之因應作為,以及其對我們第四季營運的相關預估影響。最後我會交給 Jay,由他更詳細說明第三季結果與財務展望。之後我們將進行問答。

  • As you saw in our press release, Baxter delivered solid third quarter results on both the top and bottom lines. You'll recall that we closed our acquisition of Claris Injectables on July 27. Our third quarter performance includes $27 million in sales from Claris. Sales growth in the quarter was 6% on a reported constant currency and operational basis. Operational sales are adjusted for the impact of foreign exchange, generic competition for U.S. cyclophosphamide, the Claris acquisition and the previously communicated selected strategic product exits the company has undertaken.

    如同各位在新聞稿中所見,百特第三季在營收與獲利兩端(top and bottom lines)皆交出穩健成果。各位也記得,我們已於 7 月 27 日完成對 Claris Injectables 的收購。我們第三季表現包含來自 Claris 的 2,700 萬美元銷售額。本季銷售成長在申報口徑、固定匯率(constant currency)與營運基礎(operational basis)下均為 6%。營運銷售額已就外匯影響、美國 cyclophosphamide 的學名藥競爭、Claris 收購案,以及公司先前已溝通之特定策略性產品退出所帶來的影響進行調整。

  • In the third quarter, we realized our strongest growth of the year, driven by continued strength in the U.S., particularly in Fluid Systems, Pharmaceuticals, including Claris, and renal therapies. Internationally, we saw a good performance across both the Hospital Products and Renal businesses.

    第三季我們實現了今年最強勁的成長,主要受美國市場持續強勁所帶動,尤其是在輸液系統(Fluid Systems)、製藥業務(含 Claris)以及腎臟治療。在國際市場方面,我們在醫院產品(Hospital Products)與腎臟業務(Renal)兩大業務均有良好表現。

  • On the bottom line, adjusted earnings were $0.64 per diluted share, increasing 14% over the prior year period. This reflects solid top line growth and improved gross margins, driven by favorable mix in the quarter as well as positive contributions from our ongoing business transformation efforts. Our company-wide results for the quarter reflect our focus on disciplined execution to drive improved operational performance. We will continue to implement actions to support our business transformation while also investing in the businesses, both organically and inorganically, to drive innovation and growth.

    在獲利端,調整後每股稀釋盈餘為 0.64 美元,較去年同期成長 14%。這反映了穩健的營收成長與毛利率改善,主要由本季有利的產品組合(mix)以及我們持續推動的業務轉型所帶來的正面貢獻所驅動。本季全公司層級的結果,反映我們專注於以嚴謹執行來推動營運表現改善。我們將持續推動支持業務轉型的各項行動,同時也會在各項業務上進行投資,包含有機與無機成長,以推動創新與成長。

  • The Claris acquisition represents an example of this commitment. This acquisition allows us to build a broader presence in the generic injectable pharmaceuticals market. The early market response has been positive, with customers welcoming this addition to the expanding Baxter portfolio. We will continue to build on our momentum and commercial synergies as we launch additional molecules going forward. The molecules being advanced in the generic injectables pipeline represent a combination of internal development and external strategic partnerships.

    Claris 收購案就是此一承諾的例證。此收購使我們得以在學名注射劑製藥市場建立更廣泛的布局。早期市場反應正面,客戶也樂見此一新增項目納入持續擴大的百特產品組合。隨著未來推出更多分子(molecules),我們將持續在既有動能與商業協同效益上再接再厲。目前推進中的學名注射劑產品線(pipeline)分子,結合了內部開發與外部策略合作夥伴關係。

  • Our top priority during these early months of integration is to bring Claris fully online with Baxter's systems and processes. We have focused on bringing Claris up to Baxter's global quality standards and have taken actions to support this critical objective. We have made progress since the acquisition closed, and we'll maintain this emphasis in the months ahead. M&A deals like Claris will continue to play an important role in building out our portfolio and pipeline across our key growth categories and adjacencies.

    在整合初期的這幾個月,我們的首要任務是讓 Claris 完整導入百特的系統與流程。我們聚焦於使 Claris 達到百特的全球品質標準,並已採取行動以支持此一關鍵目標。自收購完成以來我們已取得進展,未來數月也將維持此一重點。像 Claris 這樣的併購交易,將持續在我們的關鍵成長類別及其相鄰領域中,扮演擴充產品組合與研發管線的重要角色。

  • Our third quarter highlights also demonstrate the transformative and accelerating tempo of innovation of the company. During the quarter, we upgraded the SIGMA SPECTRUM infusion system with the launch of DeviceVue advanced asset tracking system. Baxter is the first and only smart infusion pump manufacturer to offer a tagless end-to-end asset tracking application, designed in consultation with our customers to drive operational efficiencies and help maximize the clinical value of their pump investments.

    我們第三季的亮點也展現公司創新步調的轉型與加速。本季我們推出 DeviceVue 進階資產追蹤系統,藉此升級 SIGMA SPECTRUM 輸注系統。百特是第一家也是唯一一家智慧輸注幫浦製造商,提供無需標籤(tagless)的端到端資產追蹤應用;該方案在與客戶諮詢下設計,旨在提升營運效率,並協助客戶將其幫浦投資的臨床價值最大化。

  • In our chronic Renal business, we have now enrolled the first patient in our U.S. clinical trial for HDx therapy enabled by THERANOVA. This is a crucial step in bringing the benefits of THERANOVA to patients in the U.S. market. THERANOVA technology is designed to closely mimic the natural kidney through clearance of certain molecules during dialysis. It is already available in several markets worldwide, including Colombia, where we have just launched a second trial of the technology.

    在我們的慢性腎臟業務方面,我們已在美國針對由 THERANOVA 支援的 HDx 治療之臨床試驗中,完成首位病患收案。這是將 THERANOVA 的效益帶給美國市場病患的關鍵一步。THERANOVA 技術的設計,是在透析過程中清除特定分子,以更貼近模擬天然腎臟的功能。該技術已在全球多個市場上市,包括哥倫比亞;我們也剛在當地啟動該技術的第二項試驗。

  • In acute therapies, we have just launched the first 3-in-1 set for use in continuous renal replacement therapy, CRRT, and sepsis management protocols. This is a label expansion for our oXIRIS blood purification set and adds to Baxter's multi-organ therapy offering, utilizing the PRISMAFLEX system. The oXIRIS label expansion takes effect in more than 30 countries in Europe as well as geographies in the Middle East and Africa. These highlights represent a small fraction of our activity and ongoing investment focused on supporting new products, their indications and new research. These investments are critical for fueling our continued growth, hand-in-hand with improved efficiencies [in BD] and disciplined execution.

    在急性治療方面,我們剛推出首款 3 合 1 組件(3-in-1 set),可用於連續性腎臟替代治療(CRRT)與敗血症管理流程。這是我們 oXIRIS 血液淨化組件的適應症標示擴增(label expansion),並透過 PRISMAFLEX 系統,進一步強化百特的多器官治療產品組合。oXIRIS 的標示擴增將在歐洲 30 多個國家,以及中東與非洲的部分地區生效。上述亮點僅占我們活動與持續投資的一小部分,這些投入聚焦於支持新產品、其適應症與新研究。這些投資對於推動我們持續成長至關重要,並將與提升效率([in BD])及嚴謹執行相輔相成。

  • Before turning it over to Jay, let me take a moment to address the natural disasters that have overwhelmed parts of the Americas and the Caribbean in recent weeks. We mobilized quickly in the aftermath of each of these catastrophes through a combination of product donations, financial assistance, on-the-ground support and employees going above and beyond [the help] to help maintain patient access through our life-sustaining products and therapies. This work continues.

    在交給 Jay 之前,讓我先花點時間談談近幾週席捲美洲與加勒比海部分地區的天然災害。在每起災難發生後,我們迅速動員,結合產品捐贈、財務援助、第一線支援,以及員工超越職責的投入,協助透過我們維持生命的產品與療法,確保病患持續取得治療。這項工作仍在持續進行。

  • In an update to the press release issued October 12, the FDA has granted 2 new approvals for regulatory discretion to temporarily import certain products from our facilities in Canada and Mexico. We now have 4 sites approved to help address demand in the U.S. market.

    在 10 月 12 日發布的新聞稿更新中,FDA 已新增核准 2 項「監管裁量」許可,允許我們暫時自加拿大與墨西哥的廠區進口特定產品。目前共有 4 個據點獲准協助因應美國市場需求。

  • As it relates to product supply from Puerto Rico, we have targeted recovery strategies in place and are continuing to do everything we can to help mitigate patient and provider disruptions. As mentioned in the press release, even with the contribution of special import approvals from other sites and expected increased production in Puerto Rico in the weeks ahead, we will not be able to fully bridge the gap in demand in the fourth quarter. Accordingly, we currently project the aftermath of Hurricane Maria will negatively impact fourth quarter revenue by approximately $70 million. However, we expect that related effect on adjusted earnings will be offset through positive performance in other areas of the business. In terms of projected recovery dates, a limited number of products won't return to [health's] inventory levels until the first quarter 2018. However, we currently expect that a number of product [firms] will return to normal supply by the end of this year. We fully understand and regret the hurricane-related inventory impact affecting our customers. Restoring reliable product supply remains our collective priority. Disruptions like this, in whatever form they may take, are an inevitable part of doing business. What matters is our ability to prepare, move fast and then react swiftly while maintaining our commitments to our stakeholders. Every day we are focused on achieving our mission for patients, strengthening our fundamentals as a company and driving greater value for investors, employees and the communities where we make a difference. Tenacious execution is the path forward, and there's no letting up the piece -- the pace, rather.

    就波多黎各的產品供應而言,我們已制定具針對性的復原策略,並持續盡一切努力協助降低對病患與醫療提供者造成的中斷。如新聞稿所述,即使其他據點的特殊進口核准有所貢獻,且未來幾週波多黎各預期將提高產量,我們在第四季仍無法完全彌補需求缺口。因此,我們目前預估瑪麗亞颶風的後續影響將使第四季營收約減少 7,000 萬美元。不過,我們預期其對調整後盈餘的相關影響,將可由公司其他業務領域的正向表現所抵銷。就預估復原時點而言,少數產品要到 2018 年第一季才會回到[health's]的庫存水位。然而,我們目前預期有多項產品[firms]將在今年底前恢復正常供應。我們完全理解並對颶風造成的庫存影響、進而影響客戶深感遺憾。恢復可靠的產品供應仍是我們共同的首要任務。無論以何種形式出現,這類中斷都是經營業務不可避免的一部分。重要的是我們能否做好準備、迅速行動,並在維持對利害關係人承諾的同時快速應對。每天我們都專注於實現對病患的使命、強化公司的基本面,並為投資人、員工以及我們發揮影響力的社區創造更大價值。堅韌的執行是前進之路,我們不會放慢腳步——應該說,不會放慢節奏。

  • With that, I will pass it to Jay for a deeper dive on the third quarter performance.

    接下來,我把時間交給 Jay,請他更深入說明第三季的表現。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Thanks, Joe, and good morning, everyone. As Joe mentioned, we're pleased with our third quarter results, which represented our highest quarterly growth rate for the year. Sales in the quarter increased 6% on a reported constant currency and an operational basis. Top line growth exceeded our expectations on both the constant currency and reported basis, driven by better-than-expected contributions from Claris and cyclophosphamide as well as a favorable foreign exchange benefit from a weaker U.S. dollar.

    謝謝你,Joe,各位早安。如 Joe 所提,我們對第三季結果感到滿意,這也是今年單季最高的成長率。本季銷售額以報表口徑、固定匯率口徑及營運口徑計算皆成長 6%。在固定匯率與報表口徑下,營收成長均優於我們預期,主要受惠於 Claris 與 cyclophosphamide 的貢獻優於預期,以及美元走弱帶來的有利匯兌效益。

  • On the bottom line, adjusted earnings were $0.64 per diluted share. This exceeded our guidance of $0.58 to $0.60 per share and reflects solid top line performance and improved gross margin, driven by favorable product mix as well as the ongoing impact from our business transformation efforts. A modest benefit from other income and a lower tax rate also contributed to the results in the quarter.

    在獲利端,調整後盈餘為每股稀釋後 0.64 美元。此數字高於我們每股 0.58 至 0.60 美元的指引,反映穩健的營收表現與毛利率改善;毛利率改善主要來自有利的產品組合,以及我們業務轉型努力的持續影響。其他收入的小幅助益與較低的稅率也對本季結果有所貢獻。

  • Now I'll walk you through performance by business. I'll be speaking to growth figures on an operational basis to provide a clearer understanding of underlying performance. As a reminder, operational growth excludes the impact of foreign exchange, U.S. cyclophosphamide, Claris and select strategic product exits. I will point out that top line performance in the quarter was not materially impacted by any of the natural disasters experienced during the third quarter.

    接下來我將按業務別帶各位檢視表現。為了更清楚理解基本面表現,我將以營運口徑說明成長數據。提醒一下,營運成長不包含匯率影響、美國 cyclophosphamide、Claris,以及部分策略性產品退出的影響。我也要指出,本季營收表現並未因第三季發生的任何天然災害而受到重大影響。

  • Global sales for Hospital Products were $1.7 billion, advancing 6% operationally. Breaking this out by business, sales in Fluid Systems were $610 million, up 7% operationally. Performance was primarily driven by robust sales of IV solutions in the U.S.

    醫院產品(Hospital Products)全球銷售額為 17 億美元,營運口徑成長 6%。按業務拆分,輸液系統(Fluid Systems)銷售額為 6.10 億美元,營運口徑成長 7%。表現主要由美國靜脈輸液(IV solutions)的強勁銷售所帶動。

  • Moving to Integrated Pharmacy Solutions or IPS. Global sales were $627 million, increasing 8% operationally. Contributing to performance in the quarter were increased sales for premixed injectable drugs and a onetime benefit from an early contract settlement with one of our hospital pharmacy customers outside the U.S. Sales of U.S. cyclo were $47 million in the quarter. And as mentioned previously, Claris contributed $27 million globally.

    接著看整合藥局解決方案(Integrated Pharmacy Solutions,IPS)。全球銷售額為 6.27 億美元,營運口徑成長 8%。本季表現的貢獻因素包括預混注射劑銷售增加,以及與美國以外某家醫院藥局客戶提前結算合約所帶來的一次性收益。本季美國 cyclo 銷售額為 4,700 萬美元。此外,如先前所述,Claris 在全球貢獻 2,700 萬美元。

  • Moving to surgical care, which includes anesthesia and BioSurgery. Total sales were $338 million, increasing 6% operationally. Contributing to performance in the quarter was low double-digit growth from anesthesia and critical care products, driven by positive demand for inhaled anesthetics internationally as well as increased U.S. sales of BREVIBLOC, the fast-acting IV beta blocker. As a reminder, in the third quarter of 2016, international anesthesia sales were negatively impacted by an austerity adjustment. Globally, BioSurgery sales increased low single digits in the quarter. We expect growth in this business to continue to improve as a result of our efforts to enhance commercial effectiveness and reinvigorate the portfolio with a number of new product launches expected next year. Finally, in Hospital Products, sales in our other category were $122 million, declining 2%.

    接著看外科照護(surgical care),包含麻醉與 BioSurgery。總銷售額為 3.38 億美元,營運口徑成長 6%。本季表現的貢獻因素包括麻醉與重症照護產品呈現低雙位數成長,主要由國際市場對吸入式麻醉劑的正向需求,以及美國 BREVIBLOC(速效靜脈注射 β 阻斷劑)銷售增加所帶動。提醒一下,2016 年第三季國際麻醉銷售曾受到緊縮調整(austerity adjustment)的負面影響。在全球範圍內,BioSurgery 本季銷售額呈現低個位數成長。我們預期,隨著我們提升商業效能並透過多項預計於明年推出的新產品重新活化產品組合,該業務的成長將持續改善。最後,在醫院產品中,我們其他類別的銷售額為 1.22 億美元,下滑 2%。

  • Turning to our Renal business. Sales were $1 billion, up 6% operationally. Sales in the quarter benefited from solid performance across all lines of the business. Both our peritoneal and in-center hemodialysis businesses advanced mid-single digits globally. Notably, the in-center HD business reported positive international sales growth for the first time this year, reflecting our efforts to stabilize and improve performance in this business. The acute renal business delivered high single-digit growth globally in the quarter, driven by mid-teens growth in the U.S. and mid-single-digit growth internationally.

    接著看腎臟(Renal)業務。銷售額為 10 億美元,營運口徑成長 6%。本季銷售受惠於各業務線的穩健表現。我們的腹膜透析與院內血液透析兩項業務在全球皆呈現中個位數成長。值得注意的是,院內 HD 業務今年首次呈報國際銷售正成長,反映我們穩定並改善該業務表現的努力。急性腎臟業務本季在全球達到高個位數成長,主要由美國中十位數成長與國際中個位數成長所帶動。

  • Walking through the rest of the P&L. Our adjusted gross margin of 45.2% represents an improvement of 30 basis points over the prior year and was driven by improved pricing in select areas of the portfolio and the benefit from our business transformation efforts aimed at simplifying the portfolio to drive efficiency and reduce costs. This improvement was modestly offset by a negative impact from foreign exchange. Adjusted SG&A totaled $633 million, increasing 4%. The positive contribution from our relentless focus on effectively managing our expense base was offset by lower transition service agreement income from Shire in the quarter. In addition, we continue to make select investments in sales and marketing in key areas of the portfolio to support our growth initiatives.

    接著說明損益表其餘項目。我們的調整後毛利率為 45.2%,較去年提升 30 個基點,主要受惠於產品組合中部分領域的定價改善,以及我們推動業務轉型、以簡化產品組合來提升效率並降低成本所帶來的效益。此改善部分被匯率的負面影響小幅抵銷。調整後銷售、一般及管理費用(SG&A)合計為 6.33 億美元,增加 4%。我們持續專注於有效管理費用基礎所帶來的正面貢獻,被本季來自 Shire 的過渡服務協議(transition service agreement)收入下降所抵銷。此外,我們也持續在產品組合的關鍵領域進行選擇性銷售與行銷投資,以支持我們的成長計畫。

  • Adjusted R&D spending in the quarter of $150 million increased 16% versus the prior year, reflecting our stated intention to accelerate investments in our core growth businesses. Adjusted operating margin in the quarter was 16.3%, an improvement of 30 basis points versus the prior year and favorable to our expectations, driven primarily by improved gross margin. Net interest expense was $14 million in the third quarter. Adjusted other income totaled $12 million in the quarter, reflecting a benefit from foreign exchange gains on balance sheet positions. The adjusted tax rate was 18.9% for the quarter, which reflects a benefit from the new stock compensation guidance. And as previously mentioned, adjusted earnings of $0.64 per diluted share exceeded our guidance of $0.58 to $0.60 per share, driven by operational sense, other income benefit and a lower tax expense.

    本季經調整後的研發支出為1.5億美元,較去年同期增加16%,反映我們先前表明將加速投資於核心成長業務的意圖。本季經調整後的營業利益率為16.3%,較去年同期改善30個基點,且優於我們的預期,主要由毛利率改善所帶動。第三季淨利息費用為1,400萬美元。本季經調整後的其他收入合計1,200萬美元,反映外匯收益對資產負債表部位帶來的利益。本季經調整後的有效稅率為18.9%,反映新股權薪酬指引所帶來的稅務利益。此外,如先前所提,經調整後每股稀釋盈餘0.64美元,高於我們每股0.58至0.60美元的指引,主要受惠於營運表現、其他收入利益以及較低的稅負費用。

  • During the third quarter, we repurchased approximately $180 million or approximately 3 million shares. These targeted repurchases were more than offset by option-related dilution.

    第三季期間,我們回購約1.8億美元、約300萬股股份。這些具針對性的回購,已被與選擇權相關的稀釋效應所抵銷且有餘。

  • Before turning to our updated outlook, I will provide some commentary regarding our cash flow performance. On a year-to-date basis, we have generated free cash flow of $933 million, an improvement of more than $500 million versus the prior year and already exceeding the 2016 full year total of $905 million. Growth has been driven by strong operational performance and lower capital expenditures, along with continued focus on improving the company's working capital performance.

    在談到我們更新後的展望之前,我先就現金流表現提供一些評論。以年初至今計算,我們已產生9.33億美元的自由現金流,較去年同期改善超過5億美元,且已超越2016年全年總額9.05億美元。成長主要來自強勁的營運表現與較低的資本支出,同時也持續聚焦於改善公司的營運資金表現。

  • Let me conclude my comments this morning by providing an update on our outlook for the remainder of 2017. We expect 2017 full year sales to increase approximately 4% on a reported basis and approximately 4% on a constant currency basis. And after adjusting for U.S. cyclophosphamide impact, select strategic product exits and removing the benefit from Claris, we expect underlying operational growth of 4% to 5%.

    最後,我以更新2017年剩餘期間的展望作為今天上午評論的結語。我們預期2017年全年銷售額在報告基礎上約成長4%,以固定匯率基礎亦約成長4%。此外,在調整美國環磷醯胺(cyclophosphamide)的影響、部分策略性產品退出,並剔除Claris帶來的利益後,我們預期基礎營運成長為4%至5%。

  • I would like to point out some key assumptions reflected in our full year sales outlook. These include approximately $70 million of negative sales impact from Hurricane Maria, approximately $57 million in Claris sales and full year cyclophosphamide sales of approximately $190 million.

    我想指出幾項反映在我們全年銷售展望中的關鍵假設。其中包括:颶風瑪麗亞(Hurricane Maria)帶來約7,000萬美元的銷售負面影響、Claris銷售約5,700萬美元,以及全年環磷醯胺銷售約1.9億美元。

  • Looking at the sales outlook in more detail. We now expect growth in Hospital Products business of approximately 4% on a constant currency and 4% to 5% on an operational basis. This outlook reflects the full impact of Hurricane Maria, with approximately 80% of the lost sales realized in the IPS franchise. The remainder of the impact is reflected in the Fluid Systems franchise. Within Hospital Products franchises, we now expect Fluid Systems constant currency sales growth of 5% to 6% and approximately 7% on an operational basis. For the Integrated Pharmacy Solutions or IPS franchise, we expect constant currency sales growth of 3% to 4%. Operationally, IPS sales are expected to increase approximately 2%. As I just mentioned, IPS includes a negative impact from Hurricane Maria of approximately $55 million.

    更詳細地看銷售展望。我們目前預期醫院產品(Hospital Products)業務以固定匯率計約成長4%,以營運基礎計成長4%至5%。此展望反映颶風瑪麗亞的完整影響,其中約80%的銷售損失發生在IPS事業群(franchise)。其餘影響則反映在輸液系統(Fluid Systems)事業群。在醫院產品各事業群中,我們目前預期輸液系統以固定匯率計銷售成長5%至6%,以營運基礎計約成長7%。至於整合藥事解決方案(Integrated Pharmacy Solutions,IPS)事業群,我們預期以固定匯率計銷售成長3%至4%。以營運基礎計,IPS銷售預期約增加2%。如我剛才提到,IPS包含颶風瑪麗亞約5,500萬美元的負面影響。

  • Within surgical care, we continue to expect sales growth of approximately 4% on a constant currency basis and 4% to 5% operationally. And finally, for the Hospital Products business, we expect BPS and other to increase low single digits. For the Renal business, we continue to expect full year constant currency sales to increase approximately 3% and growth of approximately 4% operationally.

    在外科照護(surgical care)方面,我們仍預期以固定匯率計銷售成長約4%,以營運基礎計成長4%至5%。最後,就醫院產品業務而言,我們預期BPS及其他項目將以低個位數成長。在腎臟(Renal)業務方面,我們仍預期全年以固定匯率計銷售成長約3%,以營運基礎計成長約4%。

  • Moving down the P&L. We expect an adjusted operating margin of approximately 15.5% to 16%. We expect net interest expense to total between $55 million and $60 million and adjusted other income of approximately $35 million for 2017.

    接著往下看損益表(P&L)。我們預期經調整後的營業利益率約為15.5%至16%。我們預期淨利息費用合計介於5,500萬至6,000萬美元之間,且2017年經調整後的其他收入約為3,500萬美元。

  • For the year, we now expect an average adjusted tax rate of approximately 18%. For full year 2017, we anticipate a diluted average share count of approximately 555 million shares. Based on these factors, we now expect 2017 adjusted earnings, excluding special items, of $2.40 to $2.43 per diluted share. Finally, for the year, we are, once again, increasing our outlook and now expect to generate operating cash flow of approximately $1.85 billion and free cash flow of approximately $1.2 billion.

    就全年而言,我們目前預期平均經調整後的有效稅率約為18%。2017年全年,我們預估稀釋後平均股數約為5.55億股。基於上述因素,我們目前預期2017年經調整後盈餘(不含特殊項目)為每股稀釋後2.40至2.43美元。最後,就全年而言,我們再次上調展望,現預期營業現金流約為18.5億美元,自由現金流約為12億美元。

  • Specific to the fourth quarter of 2017, we expect sales growth of approximately 4% to 5% on a reported basis and approximately 2% on a constant currency basis. Operationally, sales in the fourth quarter are expected to increase 1% to 2%. I did want to note that operational sales growth includes approximately 3 points of negative impact due to Hurricane Maria. And we expect adjusted earnings, excluding special items, of $0.56 to $0.59 per diluted share. This includes a $0.06 negative earnings impact from Hurricane Maria, which is mitigated by an increase in our sales projections for U.S. cyclophosphamide and a lower-than-expected tax rate for the fourth quarter.

    針對2017年第四季,我們預期銷售在報告基礎上約成長4%至5%,以固定匯率基礎約成長2%。以營運基礎計,第四季銷售預期增加1%至2%。我也想特別指出,營運銷售成長包含因颶風瑪麗亞造成約3個百分點的負面影響。此外,我們預期經調整後盈餘(不含特殊項目)為每股稀釋後0.56至0.59美元。其中包含颶風瑪麗亞帶來每股0.06美元的負面盈餘影響,但部分被我們上調美國環磷醯胺銷售預估,以及第四季稅率低於預期所抵銷。

  • With that, we can now open up the call for Q&A.

    接下來,我們可以開始進行問答。

  • Operator

    Operator

  • (Operator Instructions) I would like to remind participants that this call is being recorded, and a digital replay will be available on the Baxter International website for 60 days at www.baxter.com. And our first question comes from Matt Taylor of Barclays.

    (接線員指示)提醒各位與會者,本次電話會議將被錄音,並將於Baxter International網站提供為期60天的數位重播,網址為www.baxter.com。第一個問題來自Barclays的Matt Taylor。

  • Matthew Charles Taylor - Director

    Matthew Charles Taylor - Director

  • I guess the first thing I just wanted to clarify is, it seems like when you are talking about your recovery efforts in Puerto Rico that there should be very little spillover into the first quarter. Is that right in terms of what you are currently projecting? And what's the risk that some of these efforts take a little bit longer to kind of shore up your supply?

    我想先釐清第一點:聽起來當你們談到在波多黎各的復原工作時,對第一季的外溢影響應該非常有限。就你們目前的預測而言,是這樣嗎?另外,這些工作可能需要更久時間才能補強供應的風險有多大?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Matt, good morning. We are -- we have 3 factories in Puerto Rico. And I think our lowest percentage of operating capacity, right now, is at probably around 70% to 80%, okay? So we will have very little impact in the first quarter. We're going to have on-hand inventory of those products towards the end of January, meaning on-hand -- meaning product in inventory that can be shipped. So nothing that we know today would prevent us from having inventory position be well positioned by the end of January. So the impact in the first -- but that doesn't mean that you are not selling the product, meaning that we have pretty good inventory levels at that moment in time. So I will say the impact in the first quarter is small. But I want to make sure that people understand that the infrastructure in Puerto Rico is devastated. So we are operating under emergency situation with generators, and we have water in our plants and everything else. So the plants are fully operational, but we need to make sure that the federal government continues to provide the support for the recovery of the island. We have one of the plants already going on to the grid, hopefully, by the end of this week. So as we continue to see progress, our confidence becomes even stronger. But based on what we know today, very little impact in the first quarter.

    Matt,早安。我們在波多黎各有3座工廠。我想我們目前最低的產能運作比例,大概在70%到80%左右,對吧?因此第一季的影響會非常小。我們會在1月底前後備妥這些產品的現有庫存,也就是現有——也就是庫存中可出貨的產品。所以就我們今天所知,沒有任何事情會阻礙我們在1月底前把庫存部位準備到位。因此第一季的影響——但這不代表你沒有在賣產品,意思是我們在那個時間點的庫存水位相當不錯。所以我會說第一季的影響很小。但我也想確保大家理解,波多黎各的基礎設施已遭到嚴重破壞。因此我們是在緊急狀態下運作,使用發電機,我們的廠區也有供水以及其他一切所需。所以工廠是完全可運作的,但我們需要確保聯邦政府持續提供支持,以協助島上的復原。我們其中一座工廠已經開始接回電網,希望在本週末前完成。因此,隨著我們持續看到進展,我們的信心也更強。但就我們今天所知,第一季的影響非常小。

  • Matthew Charles Taylor - Director

    Matthew Charles Taylor - Director

  • Okay. And then I wanted to ask one on the Renal business. If I look at the guidance for the year, it looks like you're projecting a little bit of a pick-up in the fourth quarter, and this was the first quarter that the HD business has grown in a while. Can you talk about what you are expecting going forward? And if we could see more of a pick up, I guess, in the HD business with you participating in tenders? Or what's going on there?

    好的。接著我想問一個關於腎臟業務的問題。如果我看你們今年的指引,看起來你們預期第四季會有些許回升,而這也是 HD 業務一段時間以來首次出現成長的季度。能否談談你們對未來的預期?以及如果你們參與投標,我們是否可能看到 HD 業務有更多回升?或者那邊目前是什麼情況?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Yes. We are expecting low single digits in the HD business. But one thing that we have done is we anniversaried some issues that we had in dialyzers on a global basis, primarily outside the U.S., where we encountered significant competition and price erosion; that has been anniversaried. But also, we're the second-largest manufacturer of dialyzers in the world. So we have the ability to compete very effectively outside the U.S. And I think this is one of the changes in mindset from the old Baxter to the new Baxter. You operate where you can and make sure the manufacturing is a strategic weapon for the company. So when we look at the market, we can provide the market with great products outside the U.S. in a very cost-effective manner and also profitably. So we want to make sure that we participate. Previously, here, in the company, we probably did not have that window into the opportunity. So what you see right now is a pick-up of our dialyzer business on the -- outside the U.S. market and the stabilization of our monitor sales as well. So we feel cautiously optimistic and happy with the turnaround in the HD business.

    是的。我們預期 HD 業務將呈現低個位數成長。但我們做的一件事是:我們已經度過(anniversary)先前在透析器(dialyzers)方面、全球範圍內(主要在美國以外)遇到的一些問題;當時我們面臨激烈競爭與價格侵蝕,而這些影響如今已經度過比較基期。另外,我們是全球第二大透析器製造商。因此我們有能力在美國以外市場非常有效地競爭。我認為這也是從舊 Baxter 到新 Baxter 的思維轉變之一。你要在你能夠運作的地方運作,並確保製造能力成為公司的策略性武器。因此當我們看市場時,我們能以非常具成本效益、同時也能獲利的方式,在美國以外為市場提供優質產品。所以我們希望確保自己會參與其中。過去在公司內部,我們可能沒有那樣的視角去看見這個機會。因此你現在看到的是:我們在美國以外市場的透析器業務有所回升,同時我們的監測設備(monitor)銷售也趨於穩定。所以我們抱持審慎樂觀,也對 HD 業務的扭轉感到高興。

  • Operator

    Operator

  • And our next question comes from Bob Hopkins of Bank of America.

    下一個問題來自美國銀行(Bank of America)的 Bob Hopkins。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • First, just a clarifying question. I'm sorry if I missed this, but Jay, in terms of the EPS impact of currency in 2017, can you tell us what the impact is in '17, and your thoughts on how currency is shaping up as we look forward?

    首先是一個釐清性的問題。如果我漏聽了很抱歉,但 Jay,就 2017 年匯率對 EPS 的影響而言,你能告訴我們 2017 年的影響是多少,以及你對未來匯率走勢的看法嗎?

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes, I mean, as we think about the second half of the year relative to forecast, while we have seen a fairly meaningful sales improvement relative to foreign exchange, the actual drop-through has been fairly low, so may be $0.01 or $0.02 on the bottom line. And I would characterize that as a result of a couple of things. One is given that a lot of the strength comes from euro strength, we have a very large European cost base in place, so we don't see a great benefit from the translation back of dollars of increasing euro performance. Now we are working on our European cost base and that will improve over time, but the benefit of a strong euro is a bit muted. The other factor that come into play when we think about foreign exchange is we have put on hedge positions over the last 6 quarters, hedging out euro and other currencies. And so we have a little bit of an offset. As the euro strengthens, our translation improves, but that's offset a little bit by lower gains in terms of foreign exchange on the hedge positions that we have. So in combination, I would say that while we did see a sales impact, we didn't see an attendant drop-through to the bottom line for the most part. And looking out to 2018, clearly, there is some currency strength that we're evaluating, that could have an impact, but there are a lot of different factors in play as we look to 2018.

    是的,我的意思是,當我們思考今年下半年相對於預測的情況時,雖然我們確實看到相對於外匯而言相當明顯的銷售改善,但實際落到損益表底線的穿透(drop-through)相當低,所以底線可能只有 0.01 或 0.02 美元。我會把這描述為幾個因素造成的結果。其中之一是,鑑於強勢主要來自歐元走強,而我們在歐洲有非常龐大的成本基礎,因此歐元表現提升換算回美元時,我們並沒有看到很大的好處。當然我們正在調整我們的歐洲成本基礎,這會隨時間改善,但強勢歐元帶來的效益會被稍微削弱。另一個在我們思考外匯時會起作用的因素是:過去 6 個季度我們建立了避險部位,對歐元及其他貨幣進行避險。因此會有一些抵銷效果。當歐元走強時,我們的換算(translation)會改善,但這會被我們既有避險部位在外匯方面較低的收益所部分抵銷。因此綜合來看,我會說雖然我們確實看到銷售端的影響,但大多數情況下並沒有看到相應地穿透到損益表底線。而展望 2018 年,顯然我們正在評估一些貨幣走強的情況,可能會帶來影響,但在我們看 2018 年時,仍有許多不同因素同時在發揮作用。

  • Robert Adam Hopkins - MD of Equity Research

    Robert Adam Hopkins - MD of Equity Research

  • Great. That was very thorough. And then Joe, just I was wondering if we can get an update on your latest thoughts on capital allocation, and specifically, how you're thinking about the growing free cash flow and cash that you have. If deals do not materialize, are larger buybacks what we can expect as a most likely use of cash? Or are there circumstances where you'd let cash build?

    很好。這非常詳盡。接著 Joe,我想請你更新一下你們對資本配置的最新想法,特別是你們如何看待不斷成長的自由現金流與手上的現金。如果交易沒有成形,我們是否可以預期更大規模的庫藏股回購會是最可能的用現金方式?或者在某些情況下,你們會讓現金累積在帳上?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Bob, we always prefer to invest the money back into the company. In this case, the cash flow of the company into acquisitions. When it's not possible, we're going to buy shares back, okay? But I want to make sure that it's not an exclusivity to my statement, meaning that those are not mutually exclusive. We will do both of them because I think our cash position and our ambitions in terms of targets, we can do both, buy shares and continue to pursue M&A. So I would say that large acquisitions are very difficult to come by, and the return on invested capital that they bring along is marginal. So we are focusing on molecule purchasing. We have a lot of those in process right now, tuck-ins, product lines from companies that are divesting, things such as this to augment our growth in the long term and augment our 4 pillars of growth in our business, which is the pharmaceutical business, the critical care, the surgical as well as parts of our Renal area, primarily areas that will be beneficial to us outside the U.S., in terms of buying clinics and things like that. So we find the acquisitions in these areas where we're going to execute. And we have a brand-new M&A team, and we see some really good momentum there. But it is not exclusively one or the other. Be sure that we will continue to apply our cash flow -- our growing cash flow to share buybacks and to deliver value to our shareholders, I would say, maximize value for our shareholders.

    Bob,我們一向偏好把資金再投資回公司。在這個情況下,就是把公司的現金流用於併購。當這不可行時,我們就會回購股票,好嗎?但我想確保你不要把我的說法理解成排他性,也就是說,這兩者並非互斥。我們會兩者都做,因為以我們的現金部位以及我們在標的上的企圖心,我們可以同時回購股票並持續追求併購(M&A)。所以我會說,大型併購非常難遇到,而且它們帶來的投資資本報酬率(ROIC)也相對有限。因此我們聚焦於「分子」收購(molecule purchasing)。我們目前有很多這類案子在進行中,包括補強型(tuck-ins)、從正在剝離資產的公司收購產品線等等,用以在長期增強我們的成長,並強化我們業務的四大成長支柱:製藥業務、重症照護、外科,以及腎臟領域的部分業務——主要是對我們在美國以外有利的領域,例如收購診所之類的。所以我們會在這些我們能夠執行的領域尋找併購。而且我們有一個全新的 M&A 團隊,我們看到那裡有很不錯的動能。但這不是非此即彼。請放心,我們會持續把我們的現金流——我們不斷成長的現金流——用於股票回購,並為股東創造價值;我會說,是為股東極大化價值。

  • Operator

    Operator

  • And our next question comes from Mike Weinstein of JPMorgan.

    下一個問題來自摩根大通(JPMorgan)的 Mike Weinstein。

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • I want to try and run through a couple of items. So first, in the quarter, what was your ability to capitalize on B. Braun's manufacturing challenges in the solutions business? And then could you just spend another minute on the IPS outperformance this quarter going into, obviously, a more challenging fourth quarter because of the hurricane?

    我想快速跑過幾個項目。首先,在本季度,你們在解決方案(solutions)業務方面,把握 B. Braun 製造挑戰的能力如何?另外,你能否再花一分鐘談談本季度 IPS 的超預期表現,尤其是考量到第四季因颶風而顯然會更具挑戰?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Mike, I would say that one thing that we have changed at Baxter is our view of supply chain. And this has changed significantly in the last 6 months. And the reason is that we not only now are preparing to come into the U.S. with significant volume in LVPs to help assure our customers -- our current customers that they will have LVPs. So we do have that capability coming from other plants in the Americas. And that is already advanced to a point that we're going to start seeing that volume coming into secure volume and guarantee -- help guarantee volume for our current customers in the first quarter of 2018, but also volume that will serve to consistently meet the necessities of customers that are not ours in a situation like B. Braun. So we are selling every LVP that we have today. I know the situation in U.S. is not desirable from the point of view of the providers with the current -- the competitor that you just mentioned having quality issues or supply issues, I don't know which one is what. But I know that we are doing everything we can. But in the future, to be able to capitalize on this, we're bringing significant volume into the U.S. now that has been redirected permanently from other parts of the world to the U.S. in a very cost-effective manner, and also it is approved by the agency. In terms of the fourth quarter, I think Jay was clear about the upside that we have in cyclophosphamide as we don't see a third competitor or fourth competitor coming to the market. So we will be able to offset the Hurricane Maria impact. But once you clear that impact, we also are making provisions so we can have enough SVPs. So let me clarify what SVP is. It's a small volume parenterals, and that's the product made in Puerto Rico. Puerto Rico does not make 1 liter bags, does not make 500 neither 250 ml bags, okay? So separate both of them. I think there's some misinformation going around, spread by other competitors about what makes what and who makes what. So we want to make sure that people know. We're also augmenting volume and production of SVPs coming out of Puerto Rico to be able to satisfy not only current customer, future customers. So we see the solutions business in the U.S. as a good business. Therefore, we made some permanent decisions in allocation of capacity back into the U.S. to augment current contracts and future contracts.

    Mike,我會說我們在 Baxter 改變的一件事,是我們對供應鏈的看法。而這在過去 6 個月已經有顯著改變。原因是,我們現在不僅正準備以相當大的 LVP 供應量進入美國,以協助確保我們的客戶——我們目前的客戶——能夠取得 LVP。因此,我們確實具備從美洲其他工廠供應的能力。而這件事已經推進到一個階段:我們將在 2018 年第一季開始看到這些供應量進入美國,以鎖定供應量並保證——協助保證——我們現有客戶的供應量;同時也會有供應量能在像 B. Braun 這樣的情況下,持續滿足非我們客戶的需求。所以我們目前把手上所有的 LVP 都賣出去了。我知道從醫療服務提供者的角度來看,美國目前的情況並不理想——你剛提到的那家競爭對手出現品質問題或供應問題,我不確定是哪一個。但我知道我們正在盡一切所能。但展望未來,為了能夠把握這個機會,我們正把大量供應量帶進美國;這些供應量已以非常具成本效益的方式,從世界其他地區永久轉向美國,而且也已獲主管機關核准。至於第四季,我想 Jay 已清楚說明:在 cyclophosphamide(環磷醯胺)方面,由於我們沒有看到第三或第四個競爭者進入市場,因此我們有上行空間。所以我們將能夠抵銷瑪麗亞颶風的影響。但一旦度過那段影響,我們也正在做安排,以確保我們有足夠的 SVP。讓我澄清一下 SVP 是什麼。它是 small volume parenterals(小容量注射劑),而這是波多黎各生產的產品。波多黎各不生產 1 公升袋裝,也不生產 500 或 250 毫升袋裝,好嗎?所以請把兩者分開看。我認為外面有一些錯誤資訊在流傳,是其他競爭對手散播的,關於誰生產什麼、哪裡生產什麼。所以我們要確保大家清楚了解。我們也正在增加從波多黎各出貨的 SVP 供應量與產能,以滿足不僅是現有客戶、也包括未來客戶的需求。因此,我們把美國的 solutions(輸液/溶液)業務視為一門好生意。因此,我們已做出一些永久性的決策,把產能配置回到美國,以擴增現有合約與未來合約的供應。

  • Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

    Michael Neil Weinstein - Senior Medical Technology Analyst and Head of Healthcare Group

  • Okay. And just to clarify the -- there was a piece in the IPS business internationally this quarter that you said was onetime. Could you just maybe explain what that was? And how much it was? And then Jay, just a tax rate question. You're guiding to a lower tax rate. Initially, it was at -- for the fourth quarter at 18%. Can you just speak to the sustainability of that in 2018?

    好的。另外想釐清一下——你提到本季國際 IPS 業務裡有一部分是一次性的。你能否說明那是什麼?金額是多少?然後 Jay,再問一個稅率問題。你們指引的是較低的稅率。一開始第四季是——18%。你能談談 2018 年這個水準的可持續性嗎?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • So Mike, what happened was that -- was a onetime contractual payment due to us outside the U.S. in a compounding pharmacy area and that was $20 million this quarter, okay? That's -- what we highlighted is not -- we're not going to repeat, but was a contractual paid to us. And I'll pass on to Jay to answer the second part of your question.

    所以 Mike,發生的事情是——我們在美國以外、複方藥局(compounding pharmacy)領域,依合約收到一筆一次性的款項,本季是 2,000 萬美元,好嗎?我們強調的是——這筆不會重複,但它是依合約支付給我們的款項。我把你問題的第二部分交給 Jay 來回答。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Yes. Certainly, the tax rate has trended favorably relative to our expectations. In the third quarter relative to outperformance, tax rate contributed about $0.01. And then again, in the fourth quarter, we're seeing some positive performance from tax rate. The biggest driver of this relates to FAS 123R, which is the new stock compensation guidance. At this point, it is difficult to forecast the long-term impact of that because, to a large extent, it's dictated by option exercise and the nature of those options in terms of their value relative to what's anticipated by the Black-Scholes model. So it's hard to say what the tax rate impact will be in 2018 based on these items, but we're certainly pleased with the performance that we've seen in 2017 related to this item.

    是的。當然,稅率相對於我們的預期呈現有利的走勢。第三季相對於超預期的表現,稅率貢獻約 0.01 美元。而第四季我們也再次看到稅率帶來一些正向表現。這最大的驅動因素與 FAS 123R 有關,也就是新的股票薪酬指引。就目前而言,很難預測其長期影響,因為在很大程度上,它取決於選擇權的行使,以及這些選擇權的性質——其價值相對於 Black-Scholes 模型所預期的價值。因此,基於這些項目,很難說 2018 年稅率會受到什麼影響;但我們對 2017 年在這個項目上看到的表現當然感到滿意。

  • Operator

    Operator

  • And our next question comes from David Lewis of Morgan Stanley.

    下一個問題來自 Morgan Stanley 的 David Lewis。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Joe, I wanted to follow up on one of Mike's questions on Fluid Systems. Our sense at our conference was increased enthusiasm for the ability to add capacity in the back half of this year to provide more capacity to customers next year, and you mentioned this could be a tailwind through the first quarter. Could this actually turn out to be, relative to some of the destruction of one of your competitors, a tailwind longer or have a longer duration into 2018 than just the first quarter?

    Joe,我想跟進 Mike 關於 Fluid Systems 的一個問題。我們在會議上的感受是,大家對於今年下半年能夠增加產能、以在明年為客戶提供更多供應能力的可行性更為樂觀,而你提到這可能會在第一季形成順風。相較於你們某個競爭對手遭受的一些破壞,這是否可能不只是第一季,而是在 2018 年更長時間、或更長期間成為順風?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • David, I think we don't know the extent of other people's problems. And unlike other competitors, we will not speculate what their problems are. But what we can say is what we are preparing to do. We are preparing to bring into the U.S. a strong volume of LVPs in the first quarter -- starting in the first quarter, coming from one of our factories in the Americas that is approved to ship into the U.S. already. And that will not only help secure volume for our current customers, but also open our ability to compete for secured volume for other customers, which currently are not our customers. So I'm not saying that we're going to be able to do it. I'm saying that we have the opportunity in front of us. And knowing our Baxter U.S. team, led by Scott Luce, I'll say that I have full confidence that team can deliver on the opportunities.

    David,我想我們並不知道其他人問題的程度。而且不同於其他競爭對手,我們不會去臆測他們的問題是什麼。但我們能說的是我們正在準備做什麼。我們正準備在第一季把大量 LVP 供應帶進美國——從第一季開始——來源是我們在美洲的一座工廠,該工廠已獲核准可出貨到美國。這不僅能協助我們現有客戶鎖定供應量,也能讓我們有能力去競爭、為其他目前不是我們客戶的客戶提供可確保的供應量。所以我不是說我們一定做得到。我是說我們面前有這個機會。而且以我們 Baxter 美國團隊的能力——由 Scott Luce 領導——我完全有信心該團隊能把握並交付這些機會。

  • David Ryan Lewis - MD

    David Ryan Lewis - MD

  • Okay. Maybe just 2 quick follow-ups. So Joe, obviously, last quarter, you provided an LRP in the (inaudible) association of growth of sort of 4 percentage growth for the LRP. Can you just give us a sense, kind of, roughly, is that a good proxy for how we should think about 2018 growth rates? And then for Jay, just on Claris, you were pretty confident at our conference around this, but the warning letter sort of came out here intra-quarter, more details of that letter. Are you comfortable with sort of where you are from a mediation perspective on Claris? And do you forecast any additional cost that we may not know about heading into '18?

    好的。也許再兩個快速追問。Joe,顯然上季你們在(聽不清)中提供了 LRP,提到 LRP 大約 4% 的成長。你能否讓我們大致了解一下,這是否可以作為我們思考 2018 年成長率的一個不錯的代理指標?然後給 Jay,關於 Claris:你在我們的會議上對此相當有信心,但本季中途警告信(warning letter)出來了,信件也有更多細節。就 Claris 的補救(remediation)進度而言,你對目前狀況是否感到安心?以及你是否預期在進入 2018 年時,還會有任何我們可能尚未知悉的額外成本?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • David, what we said in July about the LRP has not changed, but we would like not today to provide guidance into '18. So we'll be -- tune in first week of February, we'll tell you all about 2018. But today, I think we should focus on the third quarter of this year, which we've finished, and the quarter coming up, which we are currently on, the fourth quarter of 2018 -- 2017, I'm sorry. Let me comment on the first part of the question of Claris, and I think Jay can talk about the costs if there's something to add. We have already responded and are on schedule to deliver on every promise we made to the agency to address their concerns on every observation. So to summarize, we are on the good path of addressing, from our perspective, the issues that have been raised by the agency, okay? We knew of some of those issues ahead of time, and we already had plans before we closed this deal that we're going to put Baxter quality systems in place. We had no doubt about that. We are doing everything we can, accelerating the pace to put those in place. We feel that the value of the acquisition is still very much on target. And the value proposition has not changed, which is quality, low cost and availability of products. And I think the amount of the resources that we have deployed to Claris to resolve these issues and improve their quality systems has been second to none. Baxter does a great job in mobilizing and addressing a crisis, and they did a pretty good job. So now we feel very comfortable that everything that we are doing, we are seeing the effect and we are seeing the effect in a positive manner. Remember, I speak from our behalf, not on behalf of the agency. Second thing, the amount of money that is going to be used to remediate the quality issues that we have -- we already had most of this cost predicted. We don't think at this point in time -- I'll pass on to Jay -- there will be something there -- of larger extent because, first, we know some of them are not expensive to fix. It's just procedural things that we have to do. But I'll pass on to Jay if he has anything else to add.

    David,我們在7月對LRP所說的並沒有改變,但我們今天不希望就2018年提供指引。所以我們會——請在2月第一週收聽,我們會把2018年的情況完整告訴你。但今天,我認為我們應該聚焦在今年已經結束的第三季,以及我們目前正在進行、接下來的季度,也就是2018年第四季——2017年第四季,抱歉。我先回應Claris這個問題的第一部分,我想如果還有需要補充的,Jay可以談談成本。我們已經做出回應,並且按進度履行我們對主管機關所做的每一項承諾,以回應他們對每一項觀察事項的疑慮。總結來說,從我們的角度看,我們正走在正確的道路上,處理主管機關提出的問題,好嗎?其中一些問題我們事先就已知悉,而且在完成這筆交易之前,我們就已經規劃要導入Baxter的品質系統。對此我們毫不懷疑。我們正在盡一切努力,加快導入這些系統的速度。我們認為這項收購的價值仍然非常符合預期。而其價值主張並未改變,也就是品質、低成本與產品供應可得性。我認為我們為Claris投入的資源,用以解決這些問題並改善其品質系統,可說是無出其右。Baxter在動員並處理危機方面做得非常好,他們也做得相當不錯。因此現在我們非常有信心,我們所做的一切正在產生效果,而且我們看到的是正面的效果。請記得,我是代表我們的立場發言,而不是代表主管機關。第二點,用於改善我們所面臨品質問題的資金——其中大部分成本我們先前就已預估。我們目前不認為——我交給Jay補充——會有更大幅度的支出,因為首先,我們知道其中一些修正並不昂貴。只是我們必須完成一些程序性的事項。不過如果Jay還有其他要補充的,我就交給他。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Really not much. I mean, we have no material changes to our financial cost projections for the business. I think Joe summed up the situation very well.

    其實沒有太多要補充的。我的意思是,我們對該業務的財務成本預估沒有任何重大變動。我認為Joe已經把情況總結得非常好。

  • Operator

    Operator

  • And our next question comes from Isaac Ro of Goldman Sachs.

    下一個問題來自高盛的Isaac Ro。

  • Isaac Ro - VP

    Isaac Ro - VP

  • Wanted to ask a couple of questions about the growth strategy. First, just kind of looking internally, not a lot of attention on the call today regarding Claris in terms of the pipeline. Can you maybe just give us an update on kind of where you stand bringing some new products to market? As I recall, it was more of a 2019, 2020 story, but just looking for an update on how we should think about the contribution to organic growth?

    我想問幾個關於成長策略的問題。首先,從內部來看,今天的電話會議對於Claris在產品管線方面著墨不多。你們能否更新一下目前在推動一些新產品上市方面的進度?我記得這比較像是2019、2020年的故事,但我想了解我們應該如何看待它對內生成長的貢獻?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • We are -- innovation is picking up momentum at the company. I will say that bringing Sumant on board was a big victory for us, and he's starting to make a big difference in how we see innovation. I would say it is playing -- '19, '20 is more of a play there, but we're making everything we can today. If you see -- actually, just look at our R&D spending. It was a little up on a sequential basis. And the reason for that is we are going after some more clinical trials, something the company has shied away in the past of doing. So, we're going more after clinical trials with THERANOVA. We have clinical trials in a couple of different places. We are spending more money in our future systems. As you know, we have a new version to be submitted to the agency and then to be released, hopefully, next year of our SPECTRUM -- SIGMA SPECTRUM. We have new platforms coming up in 2020. We have our new CRRT machine coming to the U.S. in '19. We have new filtration systems going in for different types of toxins going to be launched in '19 and '20. So we have the momentum going. I think the biggest challenge that we have is to make sure that we balance the spending in R&D with the spending in the infrastructure of R&D. So as we continue to modernize and bring the right people to the company to help foment this innovation, we don't get ahead of ourselves in creating more R&D centers, which we're not going to do. As a matter of fact, we're going to reduce the amount of spending in infrastructure and increase the spending in product development. So as -- we just want to keep transparency and give you on a quarterly basis an update of some of our advancements in innovation, which is the next thing for Baxter to be successful is to combine the significant transformation of the business cost with the innovation to deliver the best [gain] to our shareholders.

    我們——公司的創新正在加速、動能正在提升。我會說,讓Sumant加入對我們而言是一大勝利,而他正開始在我們看待創新的方式上帶來很大的改變。我會說,這在'19、'20會更明顯,但我們今天也在盡一切努力推進。如果你看——其實只要看看我們的研發支出。按季來看略有上升。原因是我們正在推進更多臨床試驗,這是公司過去較少採取的作法。因此,我們正在針對THERANOVA進行更多臨床試驗。我們在幾個不同地點都有臨床試驗在進行。我們也在未來系統上投入更多資金。如你所知,我們的SPECTRUM——SIGMA SPECTRUM有一個新版本將提交主管機關審查,之後希望能在明年推出。我們在2020年還會有新平台推出。我們的新CRRT機器將於'19進入美國市場。我們也有針對不同毒素類型的新過濾系統,預計在'19與'20推出。所以我們的動能正在形成。我認為我們最大的挑戰,是確保研發支出與研發基礎設施支出之間的平衡。因此,當我們持續現代化並引進合適的人才來推動這項創新時,我們不會在建立更多研發中心上操之過急——我們也不會這麼做。事實上,我們將降低基礎設施方面的支出,並提高產品開發方面的支出。因此——我們希望保持透明度,並在每一季向各位更新我們在創新方面的一些進展;因為Baxter要成功,下一步就是把業務成本的重大轉型與創新結合起來,為股東帶來最佳的[收益]。

  • Isaac Ro - VP

    Isaac Ro - VP

  • Great. And maybe just a follow-up on the inorganic side for growth. You mentioned earlier that large transactions are difficult, and of course, the overall environment for asset prices continues to go up. So I'm curious if you could talk a little bit about the extent to which your strategy for M&A is evolving, and in particular, sort of the opportunities that you see maybe outside the U.S. that are perhaps less obvious to those of us in the U.S. market.

    很好。另外想追問一下非內生成長的部分。你先前提到大型交易很困難,當然整體資產價格環境仍在上升。所以我想請你談談你們的併購策略在多大程度上正在演變,特別是你們在美國以外可能看到的一些機會——對我們這些身在美國市場的人而言,或許沒那麼顯而易見。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • M&A follows a strategy. We don't have an M&A strategy per se. We have a strategy for every business of the company, and M&A is following that. In the past, we had those 2 not very well coupled, and now we do. Our strategy for the company is expansion inorganically not only in the U.S. but across all regions, in Europe as well as Asia with a focus in China. And we have the people being put in place to be able to scout those opportunities. We have an M&A team that is focused in bringing more deals. I'm seeing more deals now in the pipeline than I've seen before, but not deals that are -- more relevant deals, deals that have higher probability to be executed in a very large and very fast, by the way, process going on in our pharmaceutical groups. Our pharmaceutical group, led by Robert Felicelli, is now starting to accelerate, and we have identified a significant amount of opportunities in that group for growth, so -- inorganically, by the way. And so now I feel a bit more comfortable that we have the right structure and the right strategy for the company to execute on inorganic opportunities.

    併購是跟著策略走的。我們本身並沒有一個所謂的併購策略。我們對公司每一個事業都有策略,而併購是依循那些策略來推進。過去這兩者的連結不夠緊密,但現在我們已經把它們結合起來了。我們公司的策略是在美國以外也透過非內生方式擴張,涵蓋所有區域,包括歐洲與亞洲,並聚焦中國。我們也正在配置人員,以便能夠去尋找這些機會。我們有一個併購團隊,專注於帶來更多交易。我現在在管線中看到的交易比以前更多,但不是那種——而是更相關的交易、執行機率更高的交易;順帶一提,我們的製藥事業群目前正處於一個非常大、而且非常快速的流程之中。我們的製藥事業群在Robert Felicelli的帶領下正開始加速,我們已在該事業群中辨識出大量的成長機會——而且是透過非內生成長的方式。因此,我現在更有信心,我們已具備正確的組織架構與正確的公司策略,能夠執行非內生的成長機會。

  • Operator

    Operator

  • And our next question comes from Matt Miksic of UBS.

    我們的下一個問題來自瑞銀(UBS)的 Matt Miksic。

  • Matthew Stephan Miksic - Executive Director and Senior Research Analyst

    Matthew Stephan Miksic - Executive Director and Senior Research Analyst

  • So I wanted, Joe, to maybe just first follow-up on that last comment. You've made a few comments on strategic investment, perhaps preferring kind of tuck-in smaller molecules, as you've talked about. And I'd love to understand, there is clearly opportunities across your operating structure to sort of drive leverage, Claris and molecules is one and your specialty injectable platform. Surgical call points is another. And on the hospital side, on the surgery side for product lines or things like that, just love to get a sense of which elements of Baxter's infrastructure, operations, call points, sales force, distribution, adjacencies, do you see as opportunities to leverage, because I assume if you're looking at product lines, that's one of the key elements of the opportunities? And I have one follow-up.

    Joe,我想先就你剛才最後那段評論追問一下。你曾多次談到策略性投資,似乎偏好你所提到的那種補強式(tuck-in)的較小分子產品。我很想了解的是,你們的營運架構中顯然有機會在多個面向推動槓桿效益,例如 Claris 與小分子是一個面向,你們的專科注射劑平台也是一個面向。外科的銷售觸點(call points)是另一個面向。另外在醫院端、手術端,就產品線或類似事項而言,我想請你談談:Baxter 的基礎設施、營運、銷售觸點、銷售團隊、配送通路、相鄰領域(adjacencies)等哪些要素,你認為是可以加以槓桿運用的機會?因為我猜如果你們在看產品線,這應該是機會中的關鍵要素之一?我還有一個追問。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Our call points go from hospital to home. In the hospital side, we have, in the U.S. and large geographies around the globe, a very good, I would say, probably one of the best key account management groups in the industry. So our ability to put things in contract, private label products, primarily drugs for GPOs, becomes really strengthened when you're looking at these small molecules and how you bring them online. So look at Claris. Claris benefited from Scott Luce's opportunities in the U.S. Scott runs our business in the U.S. sales for the hospital business, and he immediately got some accretion going on with the Claris molecules in the U.S. So that is our sweet spot for us. We were shy away, at least in the beginning, to go into spaces that you have to create a brand-new sales force with no synergies, because the value of those acquisitions are quite dilutive to begin with. Then you look at the home. We have a sales force to call on home in our Renal business, our PD business, with significant penetration in the U.S. So the ability to put more on their bag is important to us and is also an opportunity. So the call points in surgery, for instance, we have -- we are in the ORs, but we need to find a sweet spot in the ORs [with] our sales reps can be relevant. So we're not going to look into generic instrumentation and laparoscopy stuff because those things, the market is saturated with that. There are companies that own that space, and we add no value there. But we add value to niche operations, niche spaces of therapies or procedures that we can probably have our sales force scan the bag. So we will see some movement in terms of inorganic opportunities in the future that capitalize on our sales force in the hospital surgery-wise, where we put more products in their bags, and they will probably do a great job on that.

    我們的銷售觸點涵蓋從醫院到居家。在醫院端,我們在美國以及全球多個大型地區,擁有非常強的——我會說,可能是業界最好的關鍵客戶管理團隊之一。因此,當你在看這些小分子以及如何把它們導入(上線)時,我們把產品納入合約、做自有品牌(private label)產品——主要是提供給 GPO 的藥品——的能力就會變得非常強。所以看看 Claris。Claris 受益於 Scott Luce 在美國的機會。Scott 負責我們在美國醫院業務的銷售,他立刻就讓 Claris 的小分子在美國開始帶來一些增益(accretion)。所以那是我們的甜蜜點。至少在一開始,我們會避免進入那些必須建立全新、且沒有協同效益的銷售團隊的領域,因為那類併購在初期的價值往往相當具稀釋性(dilutive)。再看居家端。我們在腎臟業務、PD(腹膜透析)業務方面有一支拜訪居家端的銷售團隊,在美國有很高的滲透率。因此,讓他們的產品包(bag)裡能多放一些產品,對我們很重要,也是一個機會。例如在外科的銷售觸點方面,我們——我們在手術室(OR)裡,但我們需要在手術室裡找到一個甜蜜點,讓我們的業務代表能夠具備相關性。所以我們不會去看一般的器械與腹腔鏡之類的產品,因為那些市場已經飽和了。有些公司已經主導了那個領域,而我們在那裡無法增加價值。但在利基手術、利基治療或手術程序的領域,我們能增加價值;在那些領域,我們大概可以讓我們的銷售團隊把產品「掃進包裡」(scan the bag)。因此,未來我們會看到一些無機會(inorganic opportunities)的動作,會利用我們在醫院外科端的銷售團隊優勢,讓他們的包裡放更多產品,而他們很可能也會把這件事做得很好。

  • Operator

    Operator

  • And our next question comes from Larry Biegelsen of Wells Fargo.

    我們的下一個問題來自富國銀行(Wells Fargo)的 Larry Biegelsen。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • So Joe, emerging markets account for about 20% of your sales, but they don't get a lot of attention on these calls. And the growth has been sluggish, I think, in the first half of the year in emerging markets for your business. What was growth like this quarter in emerging markets? And what's the outlook there? And I had a follow-up.

    Joe,新興市場約占你們銷售的 20%,但在這些電話會議上並沒有受到太多關注。而且我認為,今年上半年你們在新興市場的成長相對遲緩。這一季新興市場的成長表現如何?那邊的展望是什麼?我也有一個追問。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Yes. Larry, just want to clarify, what is called emerging markets is 23% for Baxter. So you can see Baxter different than other companies that are called peers. We have a pretty high penetration in those markets. Most of the products we sell in emerging markets are not devices per se. They're renal and they are fluids, okay? So when we look at market growth rates, and you said sluggish in the first half, we were just growing in market rates for the markets we compete. We had a pretty strong third quarter with, for instance, China at 7%, okay? That was a pretty good market growth for us. We do have depressed numbers in emerging markets because it's the place we exited the most of our IV business. So places like Turkey, like -- a reduction in volume in the Middle East, Venezuela, parts of Latin America as well as parts of Greece that we took volume down. India, we got out of 100% of fluids business in India. That's where you see a depressed number. When you remove those, you still have a pretty good strong underlying. So having a 7% growth in China, it is a great growth for us, because in China, we are in peritoneal dialysis, nutrition and IV fluids and anesthesia gases, okay? So these are the business we have there. We do a great job. We have market share leadership in almost everything we participate. China -- and China is completely going through a complete transformation, where we're going to bring more value-added fluids to the market instead of just your regular dextrose and saline. So I feel really strong about China in our LRP crossing the $1 billion mark, which I think is a challenge, but is going to be a doable challenge to the Chinese team.

    是的。Larry,我想先澄清一下,所謂新興市場對 Baxter 來說是 23%。所以你可以看到,Baxter 與其他被稱為同業(peers)的公司不同。我們在那些市場的滲透率相當高。我們在新興市場銷售的大多數產品嚴格來說不是器材。主要是腎臟相關產品以及輸液,好嗎?所以當我們看市場成長率,而你說上半年成長遲緩時,我們其實只是以我們所競爭市場的市場成長率在成長。我們第三季表現相當強勁,例如中國成長 7%,好嗎?對我們來說那是相當不錯的市場成長。我們在新興市場的數字確實偏低,因為那是我們退出最多 IV(靜脈輸注)業務的地方。因此像土耳其——以及中東的量下滑、委內瑞拉、拉丁美洲部分地區,以及希臘部分地區,我們都把出貨量(volume)降下來了。印度方面,我們已經 100% 退出印度的輸液業務。你看到的偏低數字主要來自這些因素。把這些剔除之後,底層(underlying)的表現其實仍然相當不錯且強勁。所以中國 7% 的成長對我們來說是很好的成長,因為在中國,我們布局在腹膜透析、營養、IV 輸液以及麻醉氣體,好嗎?這些就是我們在那裡的業務。我們做得非常好。幾乎在我們參與的每個領域,我們都有市占領先地位。中國——而且中國正經歷全面轉型,我們將把更多高附加價值的輸液帶到市場,而不只是一般的葡萄糖與生理食鹽水。因此,我對中國在我們長期規劃(LRP)中跨越 10 億美元門檻感到非常有信心;我認為這是個挑戰,但對中國團隊而言會是可達成的挑戰。

  • Lawrence H. Biegelsen - Senior Analyst

    Lawrence H. Biegelsen - Senior Analyst

  • Joe, just to clarify, so when the business exits end this year, we should see an improvement in your emerging market growth rate, it sounds like. And then just one for Jay. Year-to-date growth is about 5%. You did 6% in Q4 -- in Q3, I'm sorry, operational growth. It looks like adjusting for the $70 million from Puerto Rico, it's about 4% in Q4, and that's off of a little bit of an easier comp year-over-year, I believe. So maybe if you could help us just kind of bridge Q3 to Q4, what you expect to decelerate a little bit, that would be helpful.

    Joe,我想確認一下,所以當這些業務退出在今年底結束後,聽起來我們應該會看到你們新興市場的成長率有所改善。然後再問 Jay 一題。年初至今的成長大約是 5%。你們在第四季——抱歉,是第三季——的營運成長是 6%。看起來若調整波多黎各的 7,000 萬美元影響,第四季大約是 4%,而且我相信那是建立在年對年比較稍微容易一些的基期之上。所以也許你可以幫我們把第三季到第四季之間做個銜接(bridge),你預期哪些因素會讓成長稍微放緩一些,這會很有幫助。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Certainly. The primary driver, as you noted, of the sales deceleration in the fourth quarter relates to the $70 million impact from Hurricane Maria. But beyond that, as we think about comparison Q3 to Q4, as Joe mentioned in his answer to a question, we did have about $20 million related to a contract buyout, which we don't anticipate repeating in the fourth quarter. That was more of a onetime item per se, or a specific to the third quarter, I should say, item. And so if you adjust for that, the growth rate essentially comes down a point. We had anticipated that. It was no surprise, but it was part of the forecast that we put together. So what I would say, generally, is when we guided in July of this year, we said overall the business is a 4% grower from 2017 to '20. In many cases, there were quarterly fluctuations. The first quarter was above that rate. This second quarter was below. The third quarter was above. And the fourth quarter, we expect to be in line, but for the Hurricane Maria impact. So I think, largely, we're growing a little bit faster than our end markets. And then what we do is we go through a bottoms-up forecast process and isolate things like austerity measure impacts and onetime buyouts and so on and put together the forecast. So really, that's the essential commentary, I think, thinking about the fourth quarter, but no material change in trends per se. Continue to grow in line with our long-term expectations.

    當然。如你所指出的,第四季銷售放緩的主要驅動因素與瑪麗亞颶風帶來的 7,000 萬美元影響有關。但除此之外,當我們比較第三季到第四季時,正如 Joe 在回答某個問題時提到的,我們確實有約 2,000 萬美元與一項合約買斷相關,而我們不預期這會在第四季重複發生。那更像是一次性項目,或者我應該說,是特定於第三季的項目。因此如果你把那個因素調整掉,成長率基本上就會下降 1 個百分點。我們原本就預期會如此。這並不令人意外,但它是我們所彙整的預測的一部分。所以我一般會這麼說:當我們在今年 7 月給出指引時,我們表示整體業務從 2017 年到 '20 年是 4% 的成長者。在許多情況下,季度之間會有波動。第一季高於該成長率。第二季低於。第三季高於。而第四季,我們預期會與之相符,只是受到瑪麗亞颶風影響。所以我認為,大體上我們的成長略快於終端市場。接著我們會透過自下而上的預測流程,分離出像是緊縮措施影響、一次性買斷等因素,並據此彙整預測。所以我想,這就是針對第四季的核心評論;但就趨勢本身而言,沒有任何重大變化。我們將持續依照長期預期成長。

  • Operator

    Operator

  • And our next question comes from Danielle Antalffy of Leerink.

    下一個問題來自 Leerink 的 Danielle Antalffy。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Joe, I just wanted to ask about the impact of the Renal business from the Fresenius/NxStage deal. How do you think that changes the competitive dynamics? And does that change Baxter's overall view of home hemodialysis?

    Joe,我想請教關於 Fresenius/NxStage 交易對腎臟業務的影響。你認為這會如何改變競爭態勢?這是否會改變 Baxter 對居家血液透析的整體看法?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • I think the market dynamics will not change in the long term, okay? I believe that the leadership positions that we have today become the same going forward 3, 4 years out when you think about the innovations that we're bringing to the marketplace in PD with point-of-care, and also, the CRRT business with us launching our new PrisMAX platform in the U.S. as well as extracorporeal stuff that we're going to be launching in the U.S. So I would say that I can't comment on why people do things that are not related to Baxter. So I'm not making a judgment on why -- when a company bought another one. I just don't see the reason why that would affect our market in the short and long term, primarily because today, we have market share leadership in CRRT, and we are not letting up on innovation. And in PD, the same thing. So we want to make sure that our investors understand that we have a very strong pipeline going forward, and the acquisition or the merger of these 2 companies are quite immaterial to us at the moment the way we see it.

    我認為長期來看,市場動態不會改變,好嗎?我相信,當你考量我們在 PD(腹膜透析)領域以 point-of-care(床邊照護)帶到市場的創新,以及 CRRT(連續性腎臟替代治療)業務中我們在美國推出新的 PrisMAX 平台,還有我們將在美國推出的體外循環相關產品時,我們今天所擁有的領導地位在未來 3、4 年後仍會維持不變。所以我會說,我無法評論與 Baxter 無關、他人為何做某些事。因此我不會對為什麼——或當一家公司收購另一家公司時——做出評斷。我看不出那會在短期或長期影響我們市場的理由,主要是因為目前我們在 CRRT 擁有市占領先地位,而且我們不會在創新上鬆懈。在 PD 也是同樣的情況。所以我們希望投資人理解,我們未來有非常強勁的產品研發管線,而這兩家公司之間的收購或合併,就我們目前的觀點而言,對我們影響相當不大。

  • Danielle Joy Antalffy - MD, Medical Supplies and Devices

    Danielle Joy Antalffy - MD, Medical Supplies and Devices

  • Okay. And just sticking to renal, I was hoping you could talk about how to think about the drivers of the Renal business in 2018? Not asking for guidance, but just sort of you're continuing to roll out AMIA, you will anniversary some of these less favorable tender exits. So just wondering, should -- do you view 2018 as a growth acceleration year? Do we really have to wait for the on-demand PD system in 2019 before we see the Renal business pick up?

    好的。同樣聚焦在腎臟領域,我希望你能談談 2018 年腎臟業務的驅動因素該如何看待?我不是在要求提供指引,只是你們持續推廣 AMIA,也將迎來一些較不利的標案退出的周年比較。所以想請教,2018 年——你是否把它視為成長加速的一年?我們是否真的得等到 2019 年的按需 PD 系統推出後,才會看到腎臟業務回升?

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • I just want to start with the end. I will not -- I want our investors to understand that the POC, point of care, is not a driver of our business, neither is something that will transform the business and change the growth rate of the business in any way, shape or form. Remember, we are the market share leaders in PD around the globe. And so for that purpose, the growth rates of the market are primarily dictated by the growth of the disease and our growth. So I would say that you would see -- we'll continue to see a growth in patients. The patient growth has been healthy for us, and we think we'll continue to become healthier as we move forward. And the HD-negative tenders that we either did not participate or had a significant price impact, we will anniversary. So the Renal business is in good shape, and -- but we will save some of the news for '18 for February when we give guidance.

    我想先從最後一點開始。我不會——我希望投資人理解,POC(point of care,床邊照護)不是我們業務的驅動因素,也不是會以任何方式、任何形式改造業務並改變業務成長率的東西。請記得,我們在全球 PD 領域是市占領導者。因此,市場的成長率主要由疾病的成長以及我們自身的成長所決定。所以我會說,你會看到——我們將持續看到病患人數成長。病患成長對我們而言一直很健康,我們認為隨著時間推進會變得更健康。而那些 HD(血液透析)負向的標案——我們要嘛沒有參與、要嘛受到顯著的價格影響——我們也將迎來周年比較。所以腎臟業務狀況良好,而且——但我們會把一些消息留到 '18 年 2 月我們提供指引時再說。

  • Operator

    Operator

  • And our final question comes from the line of Larry Keusch of Raymond James.

    最後一個問題來自 Raymond James 的 Larry Keusch。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Joe, so maybe this is getting a little bit in the weeds, but I'm very curious about the sepsis opportunity that you sort of started to talk about and some of the clinical trialing going on. Could you just shed a little bit of light on sort of the way to think about either the opportunity or the time line here? And then I have one quick one for Jay.

    Joe,也許這有點鑽牛角尖,但我對你開始提到的敗血症機會,以及目前正在進行的一些臨床試驗非常好奇。你能否稍微說明一下,該如何看待這個機會或時間表?然後我還有一個簡短問題要問 Jay。

  • José E. Almeida - Chairman, CEO and President

    José E. Almeida - Chairman, CEO and President

  • Larry, what we find is extracorporeal technology has evolved, and our knowhow in membranes and filtration systems help us get there faster. So if you combine the fact that a patient who is in continuous renal replacement therapy in an ICU will have the probability of developing multi-organ failure, starting with the kidneys and you go lung, liver, we are developing filtration systems or membranes specifically for this. So the sepsis one is there are some toxins that our oXIRIS product will filter and is successful in Japan. We're just making these changes and creating the momentum across the globe, all the way coming to the U.S. We have a lung product that we currently distribute today, which is very effective. We also have MARS, which is used -- I was at Emory University the other day, and are extensively used there for treatment of liver toxins and is used in conjunction with our current CRRT product which is in the market, PRISMAFLEX, today. So we really like that space. We have a new General Manager for this business in a global basis. As a matter of fact, I'm going to see some revised plans this week in terms of how to expand this technology a little bit faster and a little deeper in the markets. But we're excited about those extracorporeal technologies using the current technology that we have for CRRT, but also banking on PrisMAX, which is the new platform coming out today -- coming out in the U.S. probably sometime in 2019.

    Larry,我們看到體外循環技術已經演進,而我們在膜材與過濾系統方面的專業知識能幫助我們更快達成目標。所以如果你把這點與以下事實結合起來:在 ICU 接受 CRRT(連續性腎臟替代治療)的病患,發生多重器官衰竭的機率較高,通常從腎臟開始,接著到肺、肝;我們正在為此開發專用的過濾系統或膜材。至於敗血症方面,我們的 oXIRIS 產品可以過濾某些毒素,並且已在日本取得成功。我們正在做這些改變,並在全球建立動能,一路推進到美國。我們目前也在經銷一款肺部產品,效果非常好。我們也有 MARS 系統,用於——我前幾天在 Emory University,那裡大量用於治療肝毒素,並且與我們目前市面上的 CRRT 產品 PRISMAFLEX 搭配使用。所以我們非常看好這個領域。我們已為這項業務在全球層面任命了一位新的總經理。事實上,我這週將看到一些修訂後的計畫,內容是如何更快、也更深入地在市場中擴展這項技術。但我們對這些體外循環技術感到興奮,因為它們能運用我們現有的 CRRT 技術,同時也仰賴 PrisMAX——這是目前即將推出的新平台——在美國可能會在 2019 年某個時間推出。

  • Lawrence Soren Keusch - MD

    Lawrence Soren Keusch - MD

  • Okay. Perfect. And then Jay, just quickly, obviously, working capital improvements have been a big opportunity for you guys. So just, again, remind us where you've been making the improvements in working capital and just any thoughts on opportunities as you look forward.

    好的。完美。接著,Jay,簡單快速問一下,顯然營運資金改善一直是你們的一大機會。所以再請你提醒我們,你們在哪些營運資金面向做出了改善,以及展望未來你對機會的任何看法。

  • James K. Saccaro - CFO and EVP

    James K. Saccaro - CFO and EVP

  • Sure. Really, working capital and, I would say, generally speaking, cash flow performance has been a core area of focus of the entire organization. And I think we're really pleased with the progress. On the working capital front, frankly, it's been all 3 areas that have been squarely in our focus: inventory management, days payable and DSO. And in the third quarter, we had good performance across all 3, I think, to quarter-end with days payable 49, days sales outstanding of approximately 55 and inventory on hand in the 90s. Certainly, we want to make sure we have adequate inventory on hand. And I think we've been -- with the hurricanes and so on, that number may be a little bit low relative to standard levels. So we'll look to rebuild the days inventory on hand. But overall, very pleased with the progress. We have initiatives across each of those 3 areas, along with a clear focus on CapEx with the zero-based budgeting process for CapEx. And it's just nice to see them all paying dividends.

    當然。其實,營運資金以及我會說更廣義的現金流表現,一直是整個組織的核心關注領域。而且我認為我們對進展感到非常滿意。就營運資金而言,坦白說,我們聚焦的就是三個面向:存貨管理、應付帳款天數以及DSO(應收帳款週轉天數)。第三季我們在這三項上都有不錯的表現;截至季末,應付帳款天數為49天,應收帳款週轉天數約55天,庫存持有天數在90多天。當然,我們希望確保手上有足夠的庫存。我想我們一直——受到颶風等因素影響,這個數字相較於標準水準可能略低。因此我們會著手把庫存持有天數再補回來。但整體而言,對進展非常滿意。我們在上述三個面向各自都有推動中的專案,同時也明確聚焦資本支出(CapEx),並透過資本支出的零基預算流程來管理。很高興看到這些努力都開始帶來成果。

  • Operator

    Operator

  • Thank you. And there are no further questions at this time. Ladies and gentlemen, this does conclude today's conference call with Baxter International. Thank you for participating, and everyone, have a great day.

    謝謝。目前沒有其他問題。各位女士、先生,今天與百特國際(Baxter International)的電話會議到此結束。感謝各位參與,祝大家有美好的一天。